Anavex Life Sciences Corp (AVXL)

[XenaLives]

OK - found this PR with exact title, note that REVERSAL was predicted back then for the combo which explains the patent:

New York, NY — October 29, 2013 — Anavex Life Sciences Corp. (OTCQB: AVXL) today announced that Tangui Maurice, PhD, CNRS Research Director, Head of Team 2 ‘Endogenous Neuroprotection in Neurodegenerative Diseases’, at the University of Montpellier and INSERM, will be presenting new data supporting the investigational compound ANAVEX 2-73 as a potential therapeutic for the treatment of Alzheimer’s disease. The data will be presented in a poster presentation, co-authored by Valentine Lahmy, PharmD and Vanessa Villard, PhD, Amylgen, at the Society for Neuroscience 2013 Annual Meeting, which takes place November 9-13, 2013 in San Diego, California. Anavex is a clinical stage biopharmaceutical company engaged in the development of novel drug candidates for the treatment of Alzheimer’s disease and other neurodegenerative disorders, as well as oncology therapeutics.

The findings will be presented during the following poster session:

Title: Chronic treatment with the tetrahydrofuran derivative ANAVEX 2-73, a mixed muscarinic cholinergic and sigma-1 ligand, alleviates pathology in Tg2576 mice, a transgenic Alzheimer’s disease model
Date: Saturday, November 9, 2013
Time: 4:00 PM – 5:00 PM PDT
Place: San Diego Convention Center, Halls B-H
111 W. Harbor Drive, San Diego, CA 92101
ANAVEX 2-73 is an orally available small molecule being investigated for the treatment of Alzheimer’s disease. In addition to pre-clinical data indicating that ANAVEX 2-73 has the potential to prevent, halt and/or reverse the course of Alzheimer’s disease, there was also a highly encouraging synergistic effect observed between ANAVEX 2-73 and Aricept® (donepezil). The combined therapeutics produced up to 80% greater reversal of memory loss in Alzheimer’s disease models versus when the drugs were used individually.

https://www.anavex.com/anavex-to-present-data-for-anavex-2-73-at-society-for-neuroscience-2013-annual-meeting/

Title brought me the poster:
https://anavex.com//wp-content/uploads/Chronic-Treatment-with-the-Tetrahydrofuran.pdf

Also these two papers:

Mitochondrial protection by the mixed muscarinic/s1 ligand ANAVEX2 ...
https://www.ncbi.nlm.nih.gov/pubmed/25653589
by V Lahmy - ?2015 - ?Cited by 25 - ?Related articles
Jan 20, 2015 - Mitochondrial protection by the mixed muscarinic/s1 ligand ANAVEX2-73, a tetrahydrofuran derivative, ... Alzheimer's disease (AD), the most prevalent dementia in the ... AE37), a mixed muscarinic receptor ligand and a sigma-1 receptor ... on preservation of mitochondrial integrity in Aß25-35-injected mice.

Anti-amnesic and neuroprotective potentials of the mixed muscarinic ...
https://www.ncbi.nlm.nih.gov/pubmed/20829307
by V Villard - ?2011 - ?Cited by 66 - ?Related articles
Sep 9, 2010 - 1. J Psychopharmacol. 2011 Aug;25(8):1101-17. doi: ... Anti-amnesic and neuroprotective potentials of the mixed muscarinic receptor/sigma 1 (s1) ligand ANAVEX2-73, ... binds to muscarinic acetylcholine and sigma(1) (s(1)) receptors with ... Aß(25-35) peptide, a non-transgenic Alzheimer's disease model.